Core Viewpoint - The National Healthcare Security Administration (NHSA) has drafted a consultation document for the "Pre-communication Method for Reference Drugs (Trial)" to stabilize expectations among pharmaceutical companies during the adjustment of the medical insurance drug catalog [1] Group 1: Policy Changes - The NHSA has introduced a method for selecting reference drugs during the adjustment of the medical insurance drug catalog, which serves as an important anchor for calculating drug reimbursement standards [1] - A separate communication phase for reference drugs is deemed necessary to enhance the scientific, fair, and standardized selection process through expert discussions before the catalog adjustment begins [1] Group 2: Implementation Details - The pre-communication work for reference drugs will initially focus on Class 1 new drugs, which include Class 1 chemical drugs, Class 1 therapeutic biological products, and Class 1 traditional Chinese medicines as classified by the National Medical Products Administration [1] - Class 1 new drugs that have not yet been approved but have had their market applications accepted and passed technical reviews can also apply for pre-communication [1] Group 3: Application Process - Pharmaceutical companies can voluntarily submit applications for pre-communication of reference drugs to the NHSA's Medical Price and Bidding Procurement Guidance Center, which will verify the authenticity and completeness of the materials before providing feedback on whether the application is accepted [1] - Public feedback on the consultation document can be submitted via email to the NHSA, with a deadline set for January 16, 2026, at 17:00 [1]

Core Viewpoint - The National Healthcare Security Administration (NHSA) is seeking public opinion on the draft of the "Reference Drug Communication Method (Trial)" to enhance the scientific, fair, and standardized selection of reference drugs during the adjustment of the medical insurance drug list [1] Group 1: Policy Changes - The NHSA has introduced the practice of selecting reference drugs during the adjustment of the medical insurance drug list, which serves as an important anchor for calculating drug reimbursement standards [1] - A separate communication phase for reference drugs will be established to allow experts to propose suggestions before the adjustment process begins, thereby improving the selection process [1] Group 2: Support for Innovative Drugs - The reference drug communication work will initially focus on Class 1 new drugs, which include newly registered Class 1 chemical drugs, Class 1 therapeutic biological products, and Class 1 traditional Chinese medicines [1] - Class 1 new drugs that have not yet been approved for market but have had their applications accepted and passed technical review by the National Medical Products Administration can also apply in advance [1]